Sacristán JA - Search Results

1

Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.

Sacristán JA, Gómez JC, Montejo AL, Vieta E, Gregor KJ. Sacristán JA, et al. Clin Ther. 2000 May;22(5):583-99. doi: 10.1016/s0149-2918(00)80046-6. Clin Ther. 2000. PMID: 10868556

2

The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.

Gómez JC, Sacristán JA, Hernández J, Breier A, Ruiz Carrasco P, Antón Saiz C, Fontova Carbonell E. Gómez JC, et al. Among authors: sacristan ja. J Clin Psychiatry. 2000 May;61(5):335-43. doi: 10.4088/jcp.v61n0503. J Clin Psychiatry. 2000. PMID: 10847307 Clinical Trial.

3

[Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].

Sacristán JA, Gómez JC, Ferre F, Gascón J, Pérez Bravo A, Olivares JM. Sacristán JA, et al. Actas Esp Psiquiatr. 2001 Jan-Feb;29(1):25-32. Actas Esp Psiquiatr. 2001. PMID: 11333516 Spanish.

4

Global index of safety (GIS): a new instrument to assess drug safety.

Sacristán JA, Gómez JC, Badía X, Kind P. Sacristán JA, et al. J Clin Epidemiol. 2001 Nov;54(11):1120-5. doi: 10.1016/s0895-4356(01)00384-5. J Clin Epidemiol. 2001. PMID: 11675163

5

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).

García-Cabeza I, Gómez JC, Sacristán JA, Edgell E, González de Chavez M. García-Cabeza I, et al. Among authors: sacristan ja. BMC Psychiatry. 2001;1:7. doi: 10.1186/1471-244x-1-7. Epub 2001 Dec 28. BMC Psychiatry. 2001. PMID: 11835695 Free PMC article.

6

[The costs of treatment with the new antidepressants in clinical practice].

Sacristán JA, Gilaberte I, Hylan TR, Crown WH, Bueno G, Garzón MA, Montejo AL. Sacristán JA, et al. Aten Primaria. 1999 Jan;23(1):15-6, 18, 20-5. Aten Primaria. 1999. PMID: 10079556 Spanish.

7

Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients.

Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badia X, Gómez JC. Prieto L, et al. Among authors: sacristan ja. Curr Med Res Opin. 2004 Jun;20(6):827-35. doi: 10.1185/030079904125003674. Curr Med Res Opin. 2004. PMID: 15200739

8

The validity and reliability of the global index of safety (GIS).

Prieto L, Sacristán JA, Gómez JC. Prieto L, et al. Among authors: sacristan ja. Curr Med Res Opin. 2004 Nov;20(11):1825-32. doi: 10.1185/030079904x11484. Curr Med Res Opin. 2004. PMID: 15587489

9

Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study.

Sacristán JA, Gómez JC, Martín J, García-Bernardo E, Peralta V, Alvarez E, Gurpegui M; Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Sacristán JA, et al. Clin Drug Investig. 1998;15(1):29-35. doi: 10.2165/00044011-199815010-00004. Clin Drug Investig. 1998. PMID: 18370463

10

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].

Sacristán JA, Gómez JC, Salvador-Carulla L. Sacristán JA, et al. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997 Jul-Aug;25(4):225-34. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997. PMID: 9412161 Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters